Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clonidine + flunitrazepam
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of clonidine, a centrally acting alpha-2 adrenergic receptor agonist, and flunitrazepam, a potent benzodiazepine. This combination has been studied for use in premedication before surgical procedures and for treating alcohol withdrawal syndrome. Both drugs have sedative properties that can be synergistic when combined.
02
Targets
ADRA2C (α2C)BZD site (GABA-A receptor benzodiazepine site)ADRA2A (α2A)ADRA2B (α2B)
Beyond the preview
Go deeper on clonidine + flunitrazepam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clonidine + flunitrazepam.